CCL19型
免疫疗法
医学
三阴性乳腺癌
免疫系统
树突状细胞
乳腺癌
肿瘤微环境
CD8型
癌症研究
免疫学
癌症免疫疗法
肿瘤科
癌症
内科学
趋化因子
趋化因子受体
作者
Siyu Wu,Si-Wei Zhang,Ding Ma,Yi Xiao,Liu Yin,Li Chen,Xiao-Qing Song,Xiao-Yan Ma,Ying Xu,Wen-Jun Chai,Xi Jin,Zhi-Ming Shao,Yi‐Zhou Jiang
出处
期刊:Med
[Elsevier]
日期:2023-06-01
卷期号:4 (6): 373-393.e8
被引量:6
标识
DOI:10.1016/j.medj.2023.04.008
摘要
Background The extensive involvement of dendritic cells (DCs) in immune contexture indicates their potent value in cancer immunotherapy. Understanding DC diversity in patient cohorts may strengthen the clinical benefit of immune checkpoint inhibitors (ICIs). Methods Single-cell profiling of breast tumors from two clinical trials was performed to investigate DC heterogeneity. Multiomics, tissue characterization, and pre-clinical experiments were used to evaluate the role of the identified DCs in the tumor microenvironment. Four independent clinical trials were leveraged to explore biomarkers to predict ICI and chemotherapy outcomes. Findings We identified a distinct CCL19-expressing functional state of DCs associated with favorable responses to anti-programmed death (ligand)-1 (PD-(L)1), which displayed migratory and immunomodulatory phenotypes. These cells were correlated with antitumor T cell immunity and the presence of tertiary lymphoid structures and lymphoid aggregates, defining immunogenic microenvironments in triple-negative breast cancer. In vivo, CCL19+ DC deletion by Ccl19 gene ablation dampened CCR7+CD8+ T cells and tumor elimination in response to anti-PD-1. Notably, high circulating and intratumoral CCL19 levels were associated with superior response and survival in patients receiving anti-PD-1 but not chemotherapy. Conclusions We uncovered a critical role of DC subsets in immunotherapy, which has implications for designing novel therapies and patient stratification strategies. Funding This study was funded by the National Key Research and Development Project of China, the National Natural Science Foundation of China, the Program of Shanghai Academic/Technology Research Leader, the Natural Science Foundation of Shanghai, the Shanghai Key Laboratory of Breast Cancer, the Shanghai Hospital Development Center (SHDC), and the Shanghai Health Commission.
科研通智能强力驱动
Strongly Powered by AbleSci AI